SMShufeng Ma

Shufeng Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shufeng Ma has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Ying Lin

    Cancer Research Institute, School of Basic Medical Sciences, State Key Laboratory of Multi-organ Injury Prevention and Treatment, Guangdong Province Key Laboratory of Immune Regulation and Immunotherapy, Southern Medical University, Guangzhou, China

    5 shared publications
  • Zhili Rong

    Cancer Research Institute, School of Basic Medical Sciences, State Key Laboratory of Multi-organ Injury Prevention and Treatment, Guangdong Province Key Laboratory of Immune Regulation and Immunotherapy, Southern Medical University, Guangzhou, China

    5 shared publications
  • Xin Zhang

    Cancer Research Institute School of Basic Medical Sciences State Key Laboratory of Multi‐organ Injury Prevention and Treatment Guangdong Province Key Laboratory of Immune Regulation and Immunotherapy Southern Medical University Guangzhou 510515 China

    4 shared publications
  • Hongxin Huang

    Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China

    3 shared publications
  • Jie Lv

    Cancer Research Institute, School of Basic Medical Sciences, State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Key Laboratory of Organ Failure Research (Ministry of Education), Southern Medical University, Guangzhou, China

    3 shared publications
  • Tao Huang

    Dermatology Hospital, Southern Medical University, Guangzhou, China

    3 shared publications

Latest Publications

  • Open Access

    NS1‐Induced PARP1 Phase Transitions Prolongs Host Transcriptional Pausing to Promote Influenza A Virus Replication

    by Shufeng Ma, Changyuan Kang, Xixian Liu, Lichao Yang, Mengyi Li, Yuting Ye, Jianfang Zhang, Yingjun Li, Guanghui Jin, Yang Liu, et al.

    Influenza A virus (IAV) commandeers host transcriptional machinery to replicate, but mechanisms remain elusive. CRISPR screen identifies PARP1 as a proviral factor that binds viral NS1. ATAC‑seq reveals IAV drives PARP1‑dependent chromatin remodeling at promoter‑proximal regions (−100 to +300 bp), linking PARP1 to viral RNA synthesis. Mechanistically, NS1 engages PARP1's helical domain (HD), which alone forms large, irregular condensates with low fluidity, acting as a built‑in rheostat. HD deletion confers high droplet mobility, whereas NS1 binding locks PARP1 into a hyper‑condensed, gel‑like state. This phase transition traps Pol II in prolonged pause by enriching pausing factors (SPT5 ‑PLD , NELFA, NELFE) and excluding release factors (SPT5 ‑PRD , AFF4). The paused environment is hijacked for efficient cap‑snatching and viral RNA synthesis. This proviral activity is independent of PARP1's polymerase activity, revealing a non‑canonical mechanism that complements recent reports of PARP1‑mediated antiviral ADP‑ribosylation. Targeting this phase transition, we identify tectochrysin (TEC) and isoferulic acid (IFA), which restore fluidity, reverse pausing, and suppress IAV in mice and lung organoids without toxicity. Our work establishes that NS1 coopts PARP1 phase separation via the HD rheostat to prolong transcriptional pausing, introducing ‘phase transition correction’ as an antiviral paradigm.


  • Open Access

    Engineered circular guide RNAs boost CRISPR/Cas12a- and CRISPR/Cas13d-based DNA and RNA editing

    by Xin Zhang, Xinlong Wang, Jie Lv, Hongxin Huang, Jiahong Wang, Ma Zhuo, Zhihong Tan, Guanjie Huang, Jiawei Liu, Yuchen Liu, et al.

    Background: The CRISPR/Cas12a and CRISPR/Cas13d systems are widely used for fundamental research and hold great potential for future clinical applications. However, the short half-life of guide RNAs (gRNAs), particularly free gRNAs without Cas nuclease binding, limits their editing efficiency and durability. Results: Here, we engineer circular free gRNAs (cgRNAs) to increase their stability, and thus availability for Cas12a and Cas13d processing and loading, to boost editing. cgRNAs increases the efficiency of Cas12a-based transcription activators and genomic DNA cleavage by approximately 2.1- to 40.2-fold for single gene editing and 1.7- to 2.1-fold for multiplexed gene editing than their linear counterparts, without compromising specificity, across multiple sites and cell lines. Similarly, the RNA interference efficiency of Cas13d is increased by around 1.8-fold. In in vivo mouse liver, cgRNAs are more potent in activating gene expression and cleaving genomic DNA. Conclusions: CgRNAs enable more efficient programmable DNA and RNA editing for Cas12a and Cas13d with broad applicability for fundamental research and gene therapy.


  • Open Access

    Phase-separated DropCRISPRa platform for efficient gene activation in mammalian cells and mice

    by Shufeng Ma, Kaitong Liao, Mengrao Li, Xinlong Wang, Jie Lv, Xin Zhang, Hongxin Huang, Lian Li, Tao Huang, Xiaohua Guo, et al.

    Liquid–liquid phase separation (LLPS) plays a critical role in regulating gene transcription via the formation of transcriptional condensates. However, LLPS has not been reported to be engineered as a tool to activate endogenous gene expression in mammalian cells or in vivo. Here, we developed a droplet-forming CRISPR (clustered regularly interspaced short palindromic repeats) gene activation system (DropCRISPRa) to activate transcription with high efficiency via combining the CRISPR-SunTag system with FETIDR–AD fusion proteins, which contain an N-terminal intrinsically disordered region (IDR) of a FET protein (FUS or TAF15) and a transcription activation domain (AD, VP64/P65/VPR). In this system, the FETIDR–AD fusion protein formed phase separation condensates at the target sites, which could recruit endogenous BRD4 and RNA polymerase II with an S2 phosphorylated C-terminal domain (CTD) to enhance transcription elongation. IDR-FUS9Y>S and IDR-FUSG156E, two mutants with deficient and aberrant phase separation respectively, confirmed that appropriate phase separation was required for efficient gene activation. Further, the DropCRISPRa system was compatible with a broad set of CRISPR-associated (Cas) proteins and ADs, including dLbCas12a, dAsCas12a, dSpCas9 and the miniature dUnCas12f1, and VP64, P65 and VPR. Finally, the DropCRISPRa system could activate target genes in mice. Therefore, this study provides a robust tool to activate gene expression for foundational research and potential therapeutics.


  • Open Access

    Comparison of DNA targeting CRISPR editors in human cells

    by Hongxin Huang, Weiqi Lv, Jinhe Li, Guanjie Huang, Zhihong Tan, Yongfei Hu, Shufeng Ma, Xin Zhang, Linxuan Huang, Ying Lin

    Profiling and comparing the performance of current widely used DNA targeting CRISPR systems provide the basic information for the gene-editing toolkit and can be a useful resource for this field. Herein we made a parallel comparison between the recently reported miniature Cas12f1 and the widely used Cas12a and Cas9 nucleases in mammalian cells. The results revealed that as a CRISPRa activator, Un1Cas12f1 could induce gene expression with a comparable level to these of Cas12a and Cas9, while as a cleaving editor, Cas12f1 exhibited similar properties to Cas12a, like high specificity and dominantly induced deletions over insertions, but with less activity. In contrast, wild-type SpCas9 showed the highest activity, lowest specificity, and induced balanced deletions over insertions. Thus, Cas12f1 is recommended for gene-activation-based applications, Cas12a is for therapy applications, and wild-type Cas9 is for in vitro and animal investigations. The comparison provided the editing properties of current widely used DNA-targeting CRISPR systems for the gene-editing field.

  • Open Access

    Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity

    by Hongxin Huang, Guanjie Huang, Zhihong Tan, Yongfei Hu, Lin Shan, Jiajian Zhou, Xin Zhang, Shufeng Ma, Weiqi Lv, Tao Huang, et al.

    Background: The CRISPR-Cas12a (formerly Cpf1) system is a versatile gene-editing tool with properties distinct from the broadly used Cas9 system. Features such as recognition of T-rich protospacer-adjacent motif (PAM) and generation of sticky breaks, as well as amenability for multiplex editing in a single crRNA and lower off-target nuclease activity, broaden the targeting scope of available tools and enable more accurate genome editing. However, the widespread use of the nuclease for gene editing, especially in clinical applications, is hindered by insufficient activity and specificity despite previous efforts to improve the system. Currently reported Cas12a variants achieve high activity with a compromise of specificity. Here, we used structure-guided protein engineering to improve both editing efficiency and targeting accuracy of Acidaminococcus sp. Cas12a (AsCas12a) and Lachnospiraceae bacterium Cas12a (LbCas12a). Results: We created new AsCas12a variant termed “AsCas12a-Plus” with increased activity (1.5~2.0-fold improvement) and specificity (reducing off-targets from 29 to 23 and specificity index increased from 92% to 94% with 33 sgRNAs), and this property was retained in multiplex editing and transcriptional activation. When used to disrupt the oncogenic BRAFV600E mutant, AsCas12a-Plus showed less off-target activity while maintaining comparable editing efficiency and BRAFV600E cancer cell killing. By introducing the corresponding substitutions into LbCas12a, we also generated LbCas12a-Plus (activity improved ~1.1-fold and off-targets decreased from 20 to 12 while specificity index increased from 78% to 89% with 15 sgRNAs), suggesting this strategy may be generally applicable across Cas12a orthologs. We compared Cas12a-Plus, other variants described in this study, and the reported enCas12a-HF, enCas12a, and Cas12a-ultra, and found that Cas12a-Plus outperformed other variants with a good balance for enhanced activity and improved specificity. Conclusions: Our discoveries provide alternative AsCas12a and LbCas12a variants with high specificity and activity, which expand the gene-editing toolbox and can be more suitable for clinical applications.


  • Get ready for the CRISPR/Cas system: A beginner's guide to the engineering and design of guide RNAs

    by Shufeng Ma, Jie Lv, Zinan Feng, Zhili Rong, Ying Lin

    The clustered regularly interspaced short palindromic repeats (CRISPR) system is a state‐of‐the‐art tool for versatile genome editing that has advanced basic research dramatically, with great potential for clinic applications. The system consists of two key molecules: a CRISPR‐associated (Cas) effector nuclease and a single guide RNA. The simplicity of the system has enabled the development of a wide spectrum of derivative methods. Almost any laboratory can utilize these methods, although new users may initially be confused when faced with the potentially overwhelming abundance of choices. Cas nucleases and their engineering have been systematically reviewed previously. In the present review, we discuss single guide RNA engineering and design strategies that facilitate more efficient, more specific and safer gene editing.


  • Open Access

    OSMRβ mutants enhance basal keratinocyte differentiation via inactivation of the STAT5/KLF7 axis in PLCA patients

    by Jun Liu, Junchen Chen, Yadan Zhong, Xiaoling Yu, Ping Lu, Jianqi Feng, Xin Zhang, Shufeng Ma, Chao Yang, Bin Yang, et al.